Clinical implications of discrepant results between genotypic MTBDR plus and phenotypic Löwenstein-Jensen method for isoniazid or rifampicin drug susceptibility tests in tuberculosis patients.

MLA

Kang, Ji Young, et al. “Clinical Implications of Discrepant Results between Genotypic MTBDR plus and Phenotypic Löwenstein-Jensen Method for Isoniazid or Rifampicin Drug Susceptibility Tests in Tuberculosis Patients.” Journal of Thoracic Disease, vol. 11, no. 2, Feb. 2019, pp. 400–09. EBSCOhost, https://doi.org/10.21037/jtd.2019.01.58.

APA

Kang, J. Y., Hur, J., Kim, S., Jeon, S., Lee, J., Kim, Y. J., Kim, S. C., Park, Y. J., Kim, Y. K., & Moon, H. S. (2019). Clinical implications of discrepant results between genotypic MTBDR plus and phenotypic Löwenstein-Jensen method for isoniazid or rifampicin drug susceptibility tests in tuberculosis patients. Journal of Thoracic Disease, 11(2), 400–409. https://doi.org/10.21037/jtd.2019.01.58

Chicago

Kang, Ji Young, Jung Hur, Shinyoung Kim, Sanghoon Jeon, Jaeha Lee, Youn Jeong Kim, Seok Chan Kim, Yeon Joon Park, Young Kyoon Kim, and Hwa Sik Moon. 2019. “Clinical Implications of Discrepant Results between Genotypic MTBDR plus and Phenotypic Löwenstein-Jensen Method for Isoniazid or Rifampicin Drug Susceptibility Tests in Tuberculosis Patients.” Journal of Thoracic Disease 11 (2): 400–409. doi:10.21037/jtd.2019.01.58.